(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 340.35% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.72%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Mereo Biopharma Group's revenue in 2026 is $500,000.On average, 8 Wall Street analysts forecast MREO's revenue for 2026 to be $26,358,149,485, with the lowest MREO revenue forecast at $0, and the highest MREO revenue forecast at $41,899,138,523. On average, 8 Wall Street analysts forecast MREO's revenue for 2027 to be $32,791,462,926, with the lowest MREO revenue forecast at $242,456,348, and the highest MREO revenue forecast at $87,700,882,519.
In 2028, MREO is forecast to generate $32,698,087,703 in revenue, with the lowest revenue forecast at $8,681,501,502 and the highest revenue forecast at $71,228,535,488.